Announcements
- PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024
- PHAXIAM annonce les modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 28 juin 2024
- Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 mai 2024
- PHAXIAM provides Business and Financial Update for the First Quarter of 2024
- PHAXIAM Therapeutics fait le point sur ses activités et publie l’information financière du premier trimestre 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
- PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
- PHAXIAM Therapeutics annonce le recrutement du premier patient dans l’étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus
More ▼
Key statistics
On Friday, Phaxiam Therapeutics SA (2E40:FRA) closed at 2.77, 6.14% above its 52-week low of 2.61, set on Jun 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.85 |
---|---|
High | 2.85 |
Low | 2.77 |
Bid | 2.77 |
Offer | 3.02 |
Previous close | 2.78 |
Average volume | 337.50 |
---|---|
Shares outstanding | 6.08m |
Free float | 5.60m |
P/E (TTM) | -- |
Market cap | 17.95m EUR |
EPS (TTM) | -5.56 EUR |
Data delayed at least 15 minutes, as of Jun 07 2024 20:38 BST.
More ▼